Last reviewed · How we verify
"Raltegravir" and "Zidovudine"
Raltegravir is an integrase inhibitor that blocks HIV integration into host DNA, while zidovudine is a nucleoside reverse transcriptase inhibitor that prevents HIV RNA conversion to DNA.
Raltegravir is an integrase inhibitor that blocks HIV integration into host DNA, while zidovudine is a nucleoside reverse transcriptase inhibitor that prevents HIV RNA-to-DNA conversion; together they provide dual antiretroviral activity. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | "Raltegravir" and "Zidovudine" |
|---|---|
| Also known as | "Raltegravir", "Zidovudine" |
| Sponsor | Universidad Peruana Cayetano Heredia |
| Drug class | Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitor) |
| Target | HIV integrase (raltegravir); HIV reverse transcriptase (zidovudine) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
This combination targets two critical steps of HIV replication. Raltegravir inhibits the integrase enzyme, preventing the viral genome from integrating into the host chromosome. Zidovudine inhibits reverse transcriptase, blocking the conversion of viral RNA into DNA. Together, they provide complementary antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection (treatment)
Common side effects
- Nausea
- Headache
- Diarrhea
- Anemia
- Neutropenia
- Lipoatrophy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed (PHASE2)
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Study of Options for Second-Line Effective Combination Therapy (SELECT) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "Raltegravir" and "Zidovudine" CI brief — competitive landscape report
- "Raltegravir" and "Zidovudine" updates RSS · CI watch RSS
- Universidad Peruana Cayetano Heredia portfolio CI